In yesterday’s Wall Street session, ViewRay Inc. (NASDAQ:VRAY) shares traded at $0.53, down -4.66% from the previous session.
As of this writing, 7 analysts cover ViewRay Inc. (NASDAQ:VRAY). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $2.00 and a low of $1.00, we find $1.00. Given the previous closing price of $0.56, this indicates a potential upside of 78.57 percent. VRAY stock price is now -72.27% away from the 50-day moving average and -85.27% away from the 200-day moving average. The market capitalization of the company currently stands at $103.09M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
There are 6 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $1.20 as their price target over the next twelve months.
In other news, Dempsey James F., Chief Scientific Officer sold 42,000 shares of the company’s stock on Mar 03. The stock was sold for $173,460 at an average price of $4.13. Upon completion of the transaction, the Chief Scientific Officer now directly owns 654,368 shares in the company, valued at $0.35 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 28, Director SCHNABEL SUSAN C bought 25,000 shares of the business’s stock. A total of $117,409 was incurred on buying the stock at an average price of $4.70. This leaves the insider owning 192,790 shares of the company worth $0.1 million. Insiders disposed of 843,444 shares of company stock worth roughly $0.45 million over the past 1 year. A total of 2.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VRAY stock. A new stake in ViewRay Inc. shares was purchased by TAURUS ASSET MANAGEMENT, LLC during the first quarter worth $893,000. BOOTHBAY FUND MANAGEMENT, LLC invested $716,000 in shares of VRAY during the first quarter. In the first quarter, BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. acquired a new stake in ViewRay Inc. valued at approximately $589,000. HAP TRADING, LLC acquired a new stake in VRAY for approximately $395,000. RENAISSANCE TECHNOLOGIES LLC purchased a new stake in VRAY valued at around $143,000 in the second quarter. In total, there are 236 active investors with 86.20% ownership of the company’s stock.
Thursday morning saw ViewRay Inc. (NASDAQ: VRAY) opened at $0.5621. During the past 12 months, ViewRay Inc. has had a low of $0.55 and a high of $4.96. As of last week, the company has a debt-to-equity ratio of 1.41, a current ratio of 1.20, and a quick ratio of 0.90. The fifty day moving average price for VRAY is $1.8654 and a two-hundred day moving average price translates $3.6128 for the stock.
The latest earnings results from ViewRay Inc. (NASDAQ: VRAY) was released for Mar, 2023. According to the Medical Devices Company, earnings per share came in at -$0.16, inline with analysts’ expectations of -$0.16. This compares to -$0.14 EPS in the same period last year. The company reported revenue of $22.53 million for the quarter, compared to $18.88 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 19.38 percent. For the current quarter, analysts expect VRAY to generate $19.81M in revenue.
ViewRay Inc.(VRAY) Company Profile
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.
